The ENZAMET phase 3 trial aimed to investigate the impact of enzalutamide, focusing on radiographic progression without PSA in mHSPC. Researchers observed worse overall survival in mHSPC participants with radiographic progression without prior PSA progression. ENZAMET, a randomized trial comparing enzalutamide (ENZA) to a standard non-steroidal anti-androgen (NSAA) in 1125 metastatic hormone-sensitive prostate […]...
ASCO-GU-2024
Jan 25
-Jan 27, 2024